- In: Uncategorized
- Leave a Comment
Highlights of recent US patents (issued and applications) on protein biomarkers and molecular diagnostics.
(Click on titles to view the details)
1. Gene expression markers for the diagnosis of Parkinson’s disease.
2. Epigenetic biomarker for the detection of early-onset colorectal cancer.
3. Molecular biomarker for diagnosing drug eruption risk induced by an antiepileptic drug.
4. Placenta-derived exosomal miRNA biomarkers for the diagnosis of preterm birth.
5. Circulating exosomal miRNA biomarkers for the diagnosis of non-small cell lung cancer (NSCLC).
6. Gastrointestinal microbiota as a biomarker for the diagnosis of irritable bowel syndrome (IBD).
7. Blood plasma biomarker panel for the diagnosis of Alzheimer’s disease.
8. Circulating exosomal miRNA biomarkers for the diagnosis of ovarian cancer.
9. Serum biomarker for the diagnosis of non-alcoholic fatty liver disease (NAFLD).
10. Molecular marker for the diagnosis of fibroadenoma.
11. Serum biomarkers for the diagnosis of cardiomyopathies and myocarditis.
12. Biomarker for identifying asymptomatic carrier of liver diseases.
13. Biomarker for the diagnosis of autoimmune chronic urticaria.
14. Mass spectrometry based mitochondrial DNA analysis for bioagents detection and rapid forensic analysis.
15. Diagnosing intestinal roundworm infection in dogs and cats.
16. Diagnosing cat scratch disease caused by Bartonella henselae infection.
17. Serum protein biomarker for monitor a breast cancer patient’s response to glutamine supplementation.
18. Diagnosis of colon cancer by electrochemical methods.
19. Plasma biomarkers for the diagnosis of autism.
20. Mass spectrometry methods for the diagnosis of congenital adrenal hyperplasia (CAH).
21. Adipose triglyceride lipase (ATGL) for the diagnosis of cachexia.
22. PI3K activity for the diagnosis of Fragile X syndrome (FXS).
23. Circulating N-terminal proneurotensin for the diagnosis of Crohn’s Disease or colitis ulcerosa.
24. Diagnostic and prognostic biomarkers of renal injuries and renal failure.
25. Biomarkers for differential diagnosis of pancreatic lesions.
26. Treatment of androgenetic skin disorders based on patient’s genetic information.
27. Biomarkers for the diagnosis of 22q11 deletion syndrome (DiGeorge syndrome).
How to Identify Clinically Successful Biomarkers?
This scientific blog critically analyzes potential complexities associated with current biomarker discovery approaches. According to the scientific arguments that have been put forward in this blog, thousands of biomarkers that are currently being reported may not be true biomarkers of the target disease, rather it may be a complex mixture of biomarkers, which may include target disease specific biomarker as well as biomarkers or biomolecules associated with other diseases, infections, gender, race/ethnic backgrounds, geographic-environmental factors, psychiatric condition/diseases and nutritional factors. Based on our analysis, we believe that an ideal biomarker discovery platform, which can lead to the development of reliable and robust diagnostics assays, should be developed by integrating comprehensive understanding of patients’ phenotypic, genetic and socio-environmental characteristics along with biological and functional relevance of all biomolecules that may be potentially identified and called as biomarkers. Several innovative strategies for developing rational and personalized biomarker discovery platforms have been suggested in this blog. These strategies include 1) Comprehensive genome-scale analysis based rational genetic biomarker discovery 2) Cell or tissue or organ specific function based rational or targeted biomarker discovery 3) Use of validated tissue/organ specific biomarkers or therapeutic drug targets for identifying non-invasive biomarkers, 4) Epidemiology-driven biomarker discovery for developing personalized diagnostic tools and 5) Integrated bioinformatics approaches for rational biomarker discovery. The relevance of disease prevalence and predictive value in biomarker discovery for personalized medicine, utility of rational or personalized biomarkers in clinical trials and applications of rationally identified biomarkers for diagnostics imaging or theranostics have also been discussed. Read the full blog (click on this title): Strategies for Rational and Personalized Cancer Biomarker Discovery
Potential Use of Drug Response-Efficacy Biomarkers for Predicting Life-Threatening Disease Causing Side Effects of Therapeutic Drugs
Posted September 4, 2012on:
This scientific blog analyzes potential applications of drug response-efficacy biomarkers for predicting future onset of drug therapy induced life-threatening diseases, such as cardiovascular diseases, infectious diseases and cancer. Enabling applications of drug response-efficacy biomarkers for predicting drug-induced side effects may lead to the development of “smart biomarkers”, which can reduce morbidity and mortality in patients, and can revolutionize personalized medicine approaches. In order to achieve this goal, we proposed a model for the discovery of drug response-efficacy biomarkers and the translational utilization of these biomarkers for personalized therapies. In an exploratory analysis, anti-TNF therapy response markers of rheumatoid arthritis (RA) were analyzed, by intelligent data mining and data analysis, to demonstrate that these biomarkers may be potentially used for predicting the risk in developing cardiovascular diseases (CVDs), like atherosclerosis, in RA patients. Please follow this link to read the blog: http://www.sciclips.com/sciclips/blogArticle.do?id=Potential Use of Drug Response-Efficacy Biomarkers for Predicting Life-Threatening Disease Causing Side Effects of Therapeutic Drugs
Posted August 30, 2012on:
An open access database of rheumatoid arthritis (RA) biomarker and drug discovery assays and protocols. The listed protocols are extracted from and linked to patents and journal articles. The innovative representation of protocols in this database will be a useful tool for idea/concept generation for developing innovative approaches for RA biomarker and drug discovery research. Please follow this link to see the complete list of protocols: P : http://www.sciclips.com/sciclips/bio-protocols.do?catName=Rheumatoid%20arthritis%20%28RA%29%20biomarker%20and%20drug%20discovery%20assay
An open access database of biomarker and drug discovery assays/protocols for neurodegenerative diseases. The listed protocols are extracted from and linked to patents and journal articles. The innovative representation of protocols in this database will be a useful tool for idea/concept generation for developing innovative approaches for Alzheimer’s disease and Parkinson’s disease biomarker and drug discovery research. Please follow this link to see the complete list of protocols: http://www.sciclips.com/sciclips/bio-protocols.do?catName=Neurodegenerative%20disease%20biomarker%20and%20drug%20discovery
We have launched an open access stem cell therapy database that contains comprehensive information on the therapeutic applications of stem cells for more than 300 diseases or disorders. The data was extracted from patents, patent applications and clinical trials. Highlights of the key invention and protocols/methods used for validating the therapeutic applications of various stem cell types are also included in this database. Link to the database: http://www.sciclips.com/sciclips/stem-cell-therapeutics-database-main.do
1. Cell Based Reporter Assays vs. Animal Studies in Drug Discovery- Potential Limitations, Risks and Liabilities
2. Cell based reporter assays: misleading approach in drug discovery?
3. Cancer Theranostics – Potential Applications of Cancer Biomarker Database
4. Are stem cells ready as a next generation drug discovery tool?